Saliva Proteome, Metabolome and Microbiome Signatures for Detection of Alzheimer’s Disease
2024

Saliva Biomarkers for Detecting Alzheimer's Disease

Sample size: 80 publication 10 minutes Evidence: moderate

Author Information

Author(s): François Maxime, Pascovici Dana, Wang Yanan, Vu Toan, Liu Jian-Wei, Beale David, Hor Maryam, Hecker Jane, Faunt Jeff, Maddison John, Johns Sally, Leifert Wayne

Primary Institution: CSIRO Health & Biosecurity

Hypothesis

Can saliva proteome, metabolome, and microbiome signatures be used to detect Alzheimer's disease?

Conclusion

Saliva shows potential as a non-invasive medium for early diagnosis of Alzheimer's disease.

Supporting Evidence

  • Stratifin showed a strong negative correlation with plasma pTau181 (r = −0.49, p < 0.001).
  • 3-chlorotyrosine and L-tyrosine exhibited high correlations with disease severity progression.
  • Vitamin B12 metabolism was significantly altered in saliva as Alzheimer's disease progressed.

Takeaway

Researchers found that analyzing saliva can help identify early signs of Alzheimer's disease, making it easier to diagnose without invasive procedures.

Methodology

The study involved a multi-omics analysis of saliva samples from individuals with mild cognitive impairment, Alzheimer's disease, and cognitively normal individuals.

Potential Biases

Potential bias due to the small sample size and the cross-sectional design.

Limitations

The study had a small sample size and was cross-sectional, limiting conclusions about disease progression.

Participant Demographics

80 participants: 40 cognitively normal, 20 with mild cognitive impairment, and 20 with Alzheimer's disease, matched by age and gender.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/metabo14120714

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication